Primary endpoint met in InMIND trial of tafasitamab in patients with R/R FL

On August 15, 2024, it was announced that the phase III randomized, double-blind, placebo-controlled InMIND trial (NCT04680052), investigating tafasitamab, a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, in combination with lenalidomide and rituximab compared with lenalidomide alone as an add-on to rituximab for patients with relapsed/refractory (R/R) follicular lymphoma (FL) met its primary endpoint of progression-free survival (PFS) in patients with R/R FL. In addition, no with no new safety signals were reported.

These results suggest that tafasitamab, in combination with lenalidomide and rituximab, has the potential to improve outcomes in patients with R/R FL whose disease has progressed after at least one prior therapy.

Tafasitamab has previously received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) and approval from the U.S. Food and Drug Administration (FDA) for use in combination with lenalidomide to treat adult patients with R/R diffuse large B‑cell lymphoma (DLBCL) who are ineligible for autologous stem cell transplant.